These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31978224)

  • 1. How I treat obese patients with oral anticoagulants.
    Wang TF; Carrier M
    Blood; 2020 Mar; 135(12):904-911. PubMed ID: 31978224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Anticoagulant Use in Morbid Obesity and Post Bariatric Surgery: A Review.
    Nasser MF; Jabri A; Gandhi S; Rader F
    Am J Med; 2021 Dec; 134(12):1465-1475. PubMed ID: 34403701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 4. Direct oral anticoagulants in patients with cancer.
    Bossaer JB; Covert KL
    Am J Health Syst Pharm; 2019 Jul; 76(14):1019-1027. PubMed ID: 31361880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
    Marcy TR; Truong T; Rai A
    Consult Pharm; 2015 Nov; 30(11):644-56. PubMed ID: 26629800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Atrial fibrillation: novel possibilities of anticoagulant therapy in patients subjected to cardioversion].
    Averkov OV
    Kardiologiia; 2011; 51(7):53-7. PubMed ID: 21878086
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation.
    Martin KA; Beyer-Westendorf J; Davidson BL; Huisman MV; Sandset PM; Moll S
    J Thromb Haemost; 2021 Aug; 19(8):1874-1882. PubMed ID: 34259389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NOAC or Warfarin for Atrial Fibrillation: Does Time in Therapeutic Range Matter?
    Merinopoulos I; Venables P; Chalmers I; Vassiliou V
    Recent Adv Cardiovasc Drug Discov; 2015; 10(1):60-4. PubMed ID: 26365270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism.
    Chan NC; Eikelboom JW
    Blood; 2019 May; 133(21):2269-2278. PubMed ID: 30926593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
    Akwaa F; Spyropoulos AC
    Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.
    Kido K; Ngorsuraches S
    Ann Pharmacother; 2019 Feb; 53(2):165-170. PubMed ID: 30130979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review.
    Adam SS; McDuffie JR; Ortel TL; Williams JW
    Ann Intern Med; 2012 Dec; 157(11):796-807. PubMed ID: 22928173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Oral Anticoagulants for Atrial Fibrillation in Patients After Bariatric Surgery.
    Hendricks AK; Zieminski JJ; Yao X; Dunlay SM; Sangaralingham LR; O'Meara JG; Herrin TR; Nei SD
    Am J Cardiol; 2020 Dec; 136():76-80. PubMed ID: 32941819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of anticoagulants for the treatment and prevention of venous thromboembolism in obese patients: implications for safety.
    Ihaddadene R; Carrier M
    Expert Opin Drug Saf; 2016 Jan; 15(1):65-74. PubMed ID: 26568174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
    Becattini C; Vedovati MC; Agnelli G
    Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Warfarin in non-valvular atrial fibrillation.
    Dalby AJ; Wessels P; Opie LH
    S Afr Med J; 2013 Oct; 103(12):901-4. PubMed ID: 24300625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More Medicare patients eligible for home warfarin monitoring.
    Thompson CA
    Am J Health Syst Pharm; 2008 May; 65(9):800, 802. PubMed ID: 18436725
    [No Abstract]   [Full Text] [Related]  

  • 20. Oral anticoagulant use around the time of atrial fibrillation ablation: a review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis.
    Garton AB; Dudzinski J; Kowey PR
    J Cardiovasc Electrophysiol; 2014 Dec; 25(12):1411-8. PubMed ID: 25216104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.